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creativecommons.org/disease (AD), recent studies suggest an etiologic contribution to AD pathogenesis. We used four
dimensional (4D)-flow magnetic resonance imaging (MRI) to evaluate blood flow and pulsatility
indices in the circle of Willis. We hypothesized decreased mean blood flow and increased pulsatility,
metrics indicative of poor vascular health, would be associated with cerebral atrophy and an AD ce-
rebrospinal fluid (CSF) profile.
Methods: A total of 312 patients along the AD continuum (172 middle aged, 60 cognitively healthy
older, 44 mild cognitive impairment, and 36 AD) underwent MRI, CSF, and medical examinations.
Regression was used to predict CSF biomarkers and atrophy from 4D-flow and analysis of covariance
to compare vascular health between groups.
Results: Decreased mean flow in the middle cerebral artery (MCA) and superior portion of the in-
ternal carotid artery (sICA) and increased pulsatility in the MCAwere associated with greater brain
atrophy. Decreased mean flow in the sICAwas associated with lower amyloid beta 1–42 (Ab42) in the
CSF, a pathologic biomarker profile associated with AD. Interestingly, although metrics of flow
and pulsatility differedmarkedly across the AD spectrum, therewere no significant differences in car-
diovascular risk score, mean arterial pressure, and pulse pressure across the three age-matched older
cohorts.
Discussion: By measuring intracranial arterial health directly with 4D-flowMRI, these data suggest
that intracranial arterial health is compromised in symptomatic AD. Even after accounting foruthor. Tel.: 11-608-262-9549; Fax: 11-608-265-
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neurovascular health may contribute to the etiopathogenesis of AD.
Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article
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Although viewed as separate clinical entities, the line be-
tween Alzheimer’s disease (AD) and vascular-mediated
cognitive decline is increasingly blurred. An autopsy study
found that of patients clinically diagnosed with AD, almost
half had mixed pathology, the most common of which was
vascular. This suggests that vascular pathology may be a
salient contributing feature to dementia [1,2]. Additionally,
patients with mixed pathology were more likely than those
with singular pathology to present with dementia clinically
[1]. The American Heart and Stroke Associations posit
that the synergism between AD and vascular pathology
heightens the risk of cognitive impairment. It is suggested
that the same risk factors identified for stroke may also pre-
dict AD; specifically, hypertension is believed to be a risk
factor for poor brain aging and dementia [3–5]. Providing
further credence to this intertwined relationship, autopsy
studies show that patients with AD were more likely to
have significant atherosclerotic deposits in the circle of
Willis compared with those in controls [6].
In addition to vascular pathology measured at autopsy,
intracranial blood flow has also been shown to differ
between AD patients and controls. A study using two-
dimensional (2D) phase-contrast magnetic resonance imag-
ing (MRI) in eight AD patients and nine controls found that
AD patients had 20% lower total blood flow, suggesting a
role for reduced blood flow in AD [7]. Transcranial Doppler
(TCD), an ultrasound method commonly used in clinical
practice for diagnosing emboli, stenosis, and hemorrhage,
demonstrates reduced steady-state cerebral blood flow in
AD [8]. Additionally, a TCD analysis in 103 subjects re-
ported decreased mean arterial flow and an increased pulsa-
tility index (PI) in AD patients, suggesting that TCD
screening may be able to mitigate symptomatology by iden-
tifying people who would benefit from medications to
improve cardiovascular health, and by extension, cerebro-
vascular function [9].
Pulsatility of the cerebral vessels may be especially
telling; a study of nondemented elderly participants showed
that pulse wave velocity in the brachial-ankle vascular bed, a
metric of mixed central and peripheral arterial stiffness, was
higher in individuals who were amyloid positive on Pitts-
burgh imaging compound-B imaging [10]. Another study
explored the relationship between arterial stiffness and
amyloid deposition over time, finding that a one standard de-
viation (SD) increase in central pulse wave velocity was
associated with an approximately twofold increase in amy-
loid deposition over a 2-year period [11].Recent advances in MR hardware and acquisition and
reconstruction methods have facilitated the use of 4D-flow
MRI in clinically feasible scan times [12]. Of particular in-
terest for cranial imaging is an approach called phase
contrast vastly undersampled isotropic projection imaging
(PC VIPR), which uses the concept of radial undersampling
for accelerated imaging with high spatial and temporal res-
olution [13,14]. PC VIPR simultaneously captures the
vessel anatomy as well as the vascular flow in the form of
a velocity vector field throughout the cardiac cycle and
over a large imaging volume. Subsequent postprocessing
allows for detailed hemodynamic analysis of various
vessels. Using this PC VIPR technique to analyze flow in
11 cranial vessel segments in 314 individuals across the
AD spectrum, we observed that AD patients had the
lowest intracranial arterial flow, followed by mild
cognitive impairment (MCI), than nondemented older
controls, and finally middle-aged adults exhibiting the high-
est flow [15]. The opposite relationship was observed for PI,
a surrogate metric of vessel stiffness, with the highest PI
values seen in dementia patients. These results were espe-
cially marked in the middle cerebral artery (MCA) and the
superior portion of the internal carotid artery (sICA) [15].
Given the significant differences in mean blood flow and
PI between diagnostic cohorts, the purpose of this study
was to determine the relationship between vascular health
and markers of AD, including brain atrophy as shown on
MRI, and amyloid and tau pathology measured via cerebro-
spinal fluid (CSF). Furthermore, given that clinical measures
of cardiovascular disease were significantly associated with
amyloid deposition in several studies [3,10,11], a major
focus of the present study was to determine if intracranial
4D-flow MRI might account for unique variance in our
outcome measures not accounted for by a current gold-
standard for assessing cardiovascular disease risk, the
atherosclerotic cardiovascular disease (ASCVD) risk score.2. Methods
2.1. Subject population
A total of 312 (mean age 5 64.85 years; SD, 10.26) par-
ticipants from the University of Wisconsin Alzheimer’s Dis-
ease Research Center participated in the study. The study
population spanned cognitively healthy middle-aged adults,
cognitively healthy older adults, clinically diagnosed MCI,
and dementia due to AD patients. AD and MCI patients
were recruited from local clinics, cognitively healthy older
adults were recruited from the spouses of AD and MCI
Table 1
Demographic and diagnostic information
Information
Total sample
(n 5 312)
Middle aged
(n 5 172)
Cognitively healthy
older (n 5 60) MCI (n 5 44) AD (n 5 36)
Age in years (mean: SD) 64.85: 10.26 57.62: 5.10 74.36: 5.24 73.68: 8.55 72.74: 9.88
Sex (# females, %) 189, 60.1 127, 73.8 34, 56.7 15, 34.1 13, 36.1
Parental dementia history positive (# positive, %) 207, 66.3 135, 78.5 28, 46.7 25, 56.8 19, 52.8
APOE ε4 positive (# positive, %)* 135, 43.3 72, 41.9 20, 33.3 21, 47.7 22, 61.1
Years of education (mean: SD) 15.94: 2.62 16.16: 2.32 16.42: 2.94 15.66: 2.58 14.47: 3.02
MMSE (mean: SD) 27.94: 3.17 29.46: 0.77 29.00: 1.07 26.09: 2.79 21.58: 3.71
CDR sum of boxes (mean: SD) 0.835: 1.668 0.023: 0.119 0.150: 0.394 1.932: 1.371 4.514: 1.610
CDR global (mean: SD) 0.181: 0.318 0.012: 0.076 0.058: 0.162 0.511: 0.170 0.792: 0.325
ASCVD 10-y risk score % (mean: SD) 14.76: 16.81 4.58: 4.43 26.92: 16.34 29.12: 18.72 25.90: 19.74
Diabetes (# diagnosed, %) 30, 9.6 13, 7.6 7, 11.7 8, 18.2 2, 5.6
Undergoing medical treatment for hypertension (#, %) 118, 37.8 43, 25.0 30, 50.0 26, 59.1 19, 52.8
Abbreviations: SD, standard deviation; MCI, mild cognitive impairment; AD, Alzheimer’s disease; APOE, apolipoprotein E; MMSE, mini-mental state ex-
amination; CDR, clinical dementia rating; ASCVD, atherosclerotic cardiovascular disease.
*Six subjects not genotyped (three cognitively healthy older, two MCI, one AD); positive refers to presence of at least one APOE ε4 allele.
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older participants were recruited from the community
through advertising. Diagnosis was determined by
consensus conference based on established clinical criteria
[16]. Detailed demographic data can be found in Table 1.
2.2. MR imaging protocol
Subjects were scanned using a clinical 3T MRI system
(MR750; GE Healthcare, Waukesha, WI, USA) with an 8-
channel head coil (Excite HD Brain Coil; GE Healthcare).
Four-dimensional flow MRI data were acquired with PC
VIPR [13]. Scan parameters were as follows:
venc 5 80 cm/s, imaging volume 5 22 cm3, acquired
isotropic spatial resolution 5 0.7 mm3, repetition time
(TR)/echo time (TE) 5 7.4/2.7 ms, flip angle a 5 10,
bandwidth 5 83.3 KHz, 14,000 projection angles, scan
time w 7 minutes, and retrospective cardiac gating recon-
structed into 20 cardiac phases with temporal interpolation
[17]. AT1-weighted volume was acquired in the axial plane
with a three-dimensional (3D) fast spoiled gradient echo-
sequence using the following parameters: inversion time
(TI) 5 450 ms; TR 5 8.1 ms; TE 5 3.2 ms; flip
angle 5 12; acquisition matrix 5 256 ! 256; field of
view (FOV) 5 256 mm; and slice thickness 5 1.0 mm. A
3D T2-weighted fluid attenuated inversion recovery
sequence was acquired in the sagittal plane using the
following parameters: TI 5 1868 ms, TR 5 6000 ms;
TE 5 123 ms; flip angle 5 90; acquisition matrix 5 256
! 256; FOV 5 256 mm; slice thickness 5 2.0 mm, and
no gap yielding a voxel resolution of 1 mm ! 1 mm !
2 mm. MRI images were read by one of the authors for
anomalies that required patient notification.
2.3. Flow analysis
Velocity data from the PC VIPR examinations were used
for hemodynamic evaluation. Segmentation of the arterialtree was performed in MATLAB (The MathWorks, Natick,
MA, USA) from PC angiograms generated from the 4D-
flow MRI data, whereas interactive flow visualization and
selection of planes for quantitative analysis were conducted
in EnSight (CEI, Apex, NC, USA). For this purpose, flow
analysis planes were manually placed orthogonal to the
vessel orientation in 11 vessel segments: distal cervical in-
ternal carotid artery (ICA) (left and right), distal petrous
ICA (from hereafter referred to as sICA) (left and right),
5 mm above the basilar artery origin, 5 mm from the MCA
(left and right), and the proximal posterior cerebral artery
P1 and P2 segments (left and right) (Fig. 1). Two-
dimensional cine image series with through-plane velocities
were generated from 4D-flow MRI data at the selected
planes and analyzed in a customized MATLAB tool [18].
Mean blood flow (mL/min), cross-sectional area, PI [PI 5
(Qmax2Qmin)/Qmean; Q 5 flow], and resistive index [RI
5 (Qmax2Qmin)/Qmax] were calculated for all vessel seg-
ments.
2.4. Volumetric analysis
Gray matter, white matter, and CSF volumes were deter-
mined using SPM 12 segmentation procedures (“tissue vol-
umes” utility). This computes the totals of the modulated
warped tissue segmentations [19]. Global atrophy was
defined as the CSF volume to brain volume ratio and was
calculated by dividing the CSF volume (subarachnoid and
ventricular CSF compartments) by the sum of the gray and
white matter volumes.
2.5. CSF collection
CSF collection was performed in the morning after a min-
imum 12-hour fast. The procedure was as follows: a Sprotte
spinal needle was inserted into the L3-L4 or L4-L5 vertebral
interspace and CSF was removed via slow suction. Within
30 minutes of collection, the CSF was centrifuged to remove
Fig. 1. PC VIPR angiogram. Schematic of a PC VIPR angiogram used for
quantitative flow and pulsatility analysis. Green orthogonal analysis planes
denote where measurements were taken for the 11 vessel segments. MCA
and sICA, vessels that were the subject of the present study, are labeled. Ab-
breviations: PC VIPR, phase contrast vastly undersampled isotropic projec-
tion imaging; MCA, middle cerebral artery; sICA, superior portion of the
internal carotid artery.
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propylene tubes and stored at 280C [20]. Samples were
sent in bulk for analysis at the Clinical Neurochemistry Lab-
oratory at the Sahlgrenska Academy of the University of
Gothenburg, Sweden. The CSF samples were assayed for to-
tal tau (T-tau), phosphorylated tau (P-tau181), and amyloid
beta 1–42 (Ab42) using commercially available enzyme-
linked immunosorbent assay methods (INNOTEST assays;
Fujirebio, Ghent, Belgium) as described previously
[21–23]. Board-certified laboratory technicians blinded to
clinical diagnosis performed all analyses on one occasion.
All samples were analyzed according to protocols approved
by the Swedish Board of Accreditation and Conformity
Assessment using one batch of reagents (intraassay coeffi-
cients of variation ,10%).2.6. ASCVD risk score, mean arterial pressure, and pulse
pressure calculations
The ASCVD risk score is a formula developed by the
American College of Cardiology and the American Heart
Association to estimate risk of a cardiovascular event in
the next 10 years [24]. It is an updated version of the Fra-
mingham risk score (FRS). The variables needed include
systolic blood pressure (and whether this value is medically
treated or untreated), total and high density lipoprotein
(HDL) cholesterol, age, sex, race, diabetes status, and
smoking status. These data were acquired at the clinicalvisit closest to the scan date (mean, 66.2 days; SD, 44.7).
Systolic and diastolic pressures were measured using a
brachial sphygmomanometer. Mean arterial pressure
(MAP), a metric that represents organ perfusion, was calcu-
lated according to the following formula: MAP5 1/3 (sys-
tolic pressure2diastolic pressure) 1 diastolic pressure.
Pulse pressure (PP) was calculated as the difference be-
tween systolic and diastolic pressures.
2.7. Statistical analysis
IBM SPSS version 22 was used for statistical analyses.
Linear regressions, with 4D-flow metrics as the predictor
variables and age, sex, and diagnostic group as covariates,
were performed. To control for the four specific diagnostic
categories, dummy codes were included as covariates in
the linear regression models [25]. The older adult, MCI,
and AD groups were coded relative to the middle-aged
cohort, which was hypothesized to have the least vascular
pathology, owing to the fact that they have no dementia diag-
nosis and are the youngest subjects. For atrophy analyses,
linear regressions with MCA and sICA mean blood flow
and MCA and sICA PIs as the independent variables were
performed. Degrees of freedom for all linear regression an-
alyses were included to account for the fact that not all par-
ticipants have all PC VIPR measurements, some of which
were unmeasurable due to variant anatomy. For CSF ana-
lyses, dependent variables were CSF Ab42, T-tau, and P-
tau181, and independent variables were MCA and sICA
mean blood flow and PIs. To compare vascular health be-
tween older controls and participants diagnosed with MCI
and AD, analysis of covariance models with age and gender
covariates were used, withMAP, PP, or ASCVD risk score as
the dependent variables. For MAP and PP, a covariate of
antihypertensive treatment (yes/no) was added because un-
like ASCVD, these metrics do not take into account treated
blood pressure status.3. Results
Detailed demographic and descriptive breakdown by
diagnostic cohort (172 middle aged, 60 cognitively healthy
older, 44 MCI, and 36 AD) can be found in Table 1.
3.1. ASCVD risk score, MAP, and PP analyses
The percentage risk of having a cardiovascular event in
the next 10 years was on average 4.58% (SD, 4.43), 26.92%
(SD, 16.34), 29.12% (SD, 18.72), and 25.90% (SD, 19.74)
for the middle aged, cognitively healthy older, MCI, and
AD groups, respectively. Notably, for the three older
groups, this is approximately a 10% greater score on
average than expected for adults with ideal cardiovascular
health [24]. MAP, PP, and ASCVD risk score did not differ
among the three older groups (cognitively healthy older
adults, MCI, and AD) (Fig. 2A–C). Given the skewness
of the ASCVD risk scores and high SDs, the risk scores
Fig. 2. Between-group analyses of ASCVD risk score, MAP, and pulse pressure. Graphical results of the between-diagnostic group ANCOVA analyses exam-
ining (A) ASCVD risk score, (B) pulse pressure and (C), mean arterial pressure. There is no significant difference for any of these metrics in the three older age
groups (cognitively healthy older adults, MCI, and AD) when age and gender are included as covariates. Graphical representations (means) are without adjust-
ment for covariates to ease in readability of percentage risk and blood pressure axes. Abbreviations: ASCVD, atherosclerotic cardiovascular disease;MAP,mean
arterial pressure; MCI, mild cognitive impairment; ANCOVA, analysis of covariance; AD, Alzheimer’s disease; CI, confidence interval.
S.E. Berman et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 420-428424were log transformed to achieve normality in a post hoc
analysis; similarly to that calculated with the raw scores,
no statistical difference was found between the three older
cohorts.3.2. Atrophy analyses
After accounting for diagnosis, lower mean blood flow
and higher PI each predicted a greater degree of brain atro-
phy across all participants. This was true for both
the MCA (flow and pulsatility) as well as for flow in the
sICA. For the average blood flow of the MCA left and right
vessels, a bilateral metric, the b coefficient was 20.132
(t[DF248] 5 23.206, P 5 .002) and for the sICA, the b
was 20.123 (t[DF264] 5 23.276, P 5 .001) (Fig. 3A and
B). The opposite relationship was seen for PI, with greater
PI predicting greater loss of brain volume. For the PI of
the MCA (average of left and right MCA PI), the b coeffi-Fig. 3. Lower mean blood flow is associated with a greater degree of atrophy. Sc
between mean flow and atrophy, controlling for age, gender, and diagnostic grou
Mean flow, in both the (A) superior portion of the internal carotid artery (ICA) an
subjects with lower mean flow had greater degrees of atrophy. Abbreviations: MCcient was 0.142 (t[DF120] 5 2.184, P 5 .031) (Fig. 4). PI
in the sICA did not significantly predict atrophy.3.3. CSF biomarker analyses
A linear regression controlling for age, sex, and diagnosis
found a significant positive relationship between flow in the
sICA and Ab42 in the CSF. For the average flow of the left
and right vessels, the b coefficient was 0.177 (t
[DF141] 5 2.191, P 5 .030), indicating that individuals
with lower blood flow have lower amounts of Ab42 in the
CSF, and by inference, greater amyloid deposition in the
brain (Fig. 5A). On examination of the association between
mean blood flow in the MCA and Ab42 levels in CSF, there
was a trend approaching significance; the b coefficient was
0.161 (t[DF137] 5 1.867, P 5 .064) (Fig. 5B). Pulsatility
did not predict CSF Ab42, and neither flow nor pulsatility
was significantly related to CSF markers of tau pathology.atter plot of the results of the linear regression examining the relationship
p. Atrophy is calculated as the ratio of CSF to gray matter 1 white matter.
d the (B) middle cerebral artery (MCA), negatively predict atrophy, where
I, mild cognitive impairment; AD, Alzheimer’s disease.
Fig. 4. Higher pulsatility index is associated with a greater degree of atro-
phy. Scatter plot of the results of the linear regression examining the rela-
tionship between pulsatility and atrophy, controlling for age, gender, and
diagnostic group. Atrophy is calculated as the ratio of CSF to gray
matter1white matter. Pulsatility in the middle cerebral artery (MCA) posi-
tively predicted atrophy, where subjects with higher pulsatility (stiffer ves-
sels) had greater degrees of atrophy. Abbreviations: MCI, mild cognitive
impairment; AD, Alzheimer’s disease.
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The results of this study converge with prior studies
suggesting that vascular measures are associated with AD
pathology. Intracranial blood flow was associated
with both atrophy and CSF markers of amyloid. AccurateFig. 5. Lowermean blood flow is associated with lower levels of CSFAb42. Scatter
mean blood flow and CSF Ab42, controlling for age, gender, and diagnostic group
(ICA) is associated with lower levels of Ab42 in the CSF, suggesting possible reduc
dle cerebral artery (MCA) shows a trending relationship. Abbreviations: MCI, mil
Ab42, amyloid beta 1–42.characterization of vascular pathology in vivo is important,
given that approximately 50% of individuals with clinically
diagnosed AD have mixed pathology at the time of autopsy,
the most common of which is both amyloid and infarct [2].
The interrelationship between AD pathology and vascular
health is further underscored by the fact that individuals
who have significant amyloid positivity on positron emis-
sion tomography imaging have greater vascular bed pulse
wave velocity [10,11]. The present study uniquely
examines the health of the intracranial arteries of the
circle of Willis and demonstrates that reduced blood flow
and increased PI of these arteries are associated with
various features of the AD pathologic profile.4.1. ASCVD risk score, MAP, and PP
As the ASCVD risk score has been recently imple-
mented, there is a paucity of literature regarding its rela-
tionship to AD. The earlier FRS has been extensively
examined; a study of 1755 offspring of the Framingham
cohort was studied both in 1991–1995 and again in
2005–2008. At the initial visit, the FRS was calculated,
and at the follow-up visit, memory tests administered.
The researchers found that individuals with a higher car-
diovascular risk score at midlife were more likely to expe-
rience memory decline [26]. Additionally, a study of 1202
patients from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) cohort found that patients with AD
biomarker positivity and high stroke risk (as identified by
the FRS) had the lowest cognitive performance [27]. In
contrast, a study of 82 elderly patients with mild-to-
moderate cognitive deficits (mean age, 79.0 6 5.9 years;
67.1% females) did not find that present FRS was predic-
tive of further decline [28].plot of the results of the linear regression examining the relationship between
. Lower mean flow of the (A) superior portion of the internal carotid artery
ed amyloid clearance/increased deposition in the brain. (B) Flow in the mid-
d cognitive impairment; AD, Alzheimer’s disease; CSF, cerebrospinal fluid;
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relate specifically to peripheral vessel health. In particular,
higher PP, or a greater difference between systolic and dia-
stolic pressures, is believed to be due to increased arterial
stiffness. A study of 877 participants (aged 55–91 years)
from the ADNI cohort sought to examine the relationship be-
tween PP and AD CSF biomarkers. Patients with a positive
biomarker profile were found to have greater PP than indi-
viduals who were P-tau181 negative. Subjects in their very-
old age group (80–91 years) with a higher PP or MAP at
baseline progressed more rapidly to dementia [29].
Our study suggests that intracranial 4D-flow metrics of
vascular health may be more direct predictors of AD pathol-
ogy than the ASCVD risk score, PP, and MAP. This is evi-
denced by the fact that although there is significant
difference between the three older diagnostic groups on
intracranial 4D-flow metrics, they do not differ on MAP,
PP, or ASCVD score. This suggests that intracranial blood
flow and PI in the cerebral arteries may measure intracranial
vascular health in a more specific manner than the overall
ASCVD risk score or peripheral pressure metrics, and thus
may have greater utility in the prediction of AD pathology.4.2. Atrophy
Considerable research suggests a significant contribution
of vascular pathology to cognitive decline, with a potentially
synergistic effect on cognition when combined with patho-
gnomonic AD pathology. In a neuropathologic study where
ratings of atrophy and large vessel disease were performed
by pathologists blind to study objectives, more severe
large-vessel vascular disease was associated with a greater
degree of cortical atrophy [30]. The SMArt-MR (second
manifestations of arterial disease) study sought to
investigate the vascular contributions to cognitive decline
in patients with symptomatic atherosclerotic disease. Re-
searchers found that patients with atrophy and high white
matter hyperintensity lesion volume had increased cognitive
decline compared with subjects with a lesser amount of
vascular pathology [31]. Furthermore, an interaction was
observed with brain volume and the presence of infarcts,
where subjects with brain volume reduction and infarct pa-
thology displayed perturbed executive functioning, although
this relationship was not seen in subjects with reduced brain
volume but without infarcts [32].
The additive nature of vascular/infarct and amyloid pa-
thology in increasing the odds of dementia and the incidence
of cognitive decline has been shown in myriad studies, as
discussed in the American Heart Association/American
Stroke Association scientific statement to health care profes-
sionals [4]. Our study suggests that increased loss of brain
volume due to impaired blood flow dynamics may be a bio-
logical mechanism for this additive hypothesis paradigm.
The positive correlation between 4D-flow MRI metrics of
poor vascular health (lower mean blood flow and increased
PI) and atrophy observed in our study suggests that intracra-nial cerebral artery health is an important contributor to
atrophy, and explains something beyond age-related volume
loss or volume loss expected when disease state is controlled
for in regression analyses.
4.3. CSF biomarkers
Amyloid plaque deposition in the brain parenchyma is a
hallmark of AD, and recent research has suggested an asso-
ciation of intracranial vascular health with this pathologic
marker. In a metabolic labeling study of 12 control and 12
AD subjects, production of Ab40 and Ab42 was not different
between groups, but clearance rates were significantly
reduced in AD patients [33]. Most soluble b-amyloid is
believed to be removed via paravascular clearance, suggest-
ing a role for disturbed blood flow in the pathogenesis of pla-
ques [34]. Furthermore, b-amyloid tends to cluster around
large diameter arterial vessels as opposed to smaller capil-
laries, suggesting that arterial health, such as that measured
by 4D-flow MRI, is important to investigate [35]. Probing
this relationship directly, a study of transgenic mice express-
ing human b-amyloid protein found that manipulation of ce-
rebral blood flow by aortic constriction resulted in greater
cerebral amyloid angiopathy and amyloid plaques [36].
This mechanism may support the association between
greater MCA and sICA flow and Ab42 levels in the CSF
demonstrated in our study and requires more investigation.
4.4. Limitations and future directions
One potential limitation is that analyses were conducted
across diagnostic groups; this design was chosen to examine
the full continuum of pathology across participants and
because sample sizes of the AD and MCI groups were not
large enough to have sufficient statistical power for within-
group analyses. Additionally, the ASCVD risk equation is
validated for patients aged between 40 and 79 years, and 30
subjects in this study were aged80 years. The risk equation
includes a parameter for hypertensive medication, but does
not account for type or dose. As this study design was
cross-sectional, determinants of causality cannot be made;
plans are underway, however, for participants to return for
longitudinal follow-up imaging,whichwill allowgreater abil-
ity to define the interrelationship between AD and vascular
pathologies. The middle-aged group in particular will be a
focus of future studies because they are enriched for AD
risk factors, to determine how vascular health at midlife con-
tributes to subsequent cognitive decline. Additional planned
analyses include a systematic examination of T2* scans for
cerebral microhemorrhages, as these may partially account
for the increased pulsatility seen in AD patients [37].5. Conclusions
PCVIPR is a novel 4D-flowMRImethod that can be used
to evaluate intracranial mean flow and pulsatility associated
with AD in both preclinical and disease stages. These data
S.E. Berman et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 420-428 427show that 4D-flow metrics indicative of reduced intracranial
arterial health are associated with increased cerebral atrophy
and reduced CSF levels of Ab42. Interestingly, blood flow
and PI measurements seem to capture additional information
beyond that acquired using a gold-standard vascular risk
score. This suggests that the intracranial arterial health
component of overall vascular health merits further study
to further clarify its unique role in AD pathogenesis.
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1. Systematic review: The authors surveyed the litera-
ture using standard online sources, data presented at
conferences, and discussions with collaborators.
The contribution of vascular risk factors to the etiopa-
thogenesis of Alzheimer’s disease is not completely
understood; however, there are a number of publica-
tions addressing this issue that are cited herein.
2. Interpretation: These findings support a theory by
which intracranial arterial health (mean blood flow
and pulsatility index) is related to various pathologic
changes (cerebral atrophy, cerebrospinal fluid amy-
loid beta 1–42) associated with Alzheimer’s disease.
3. Future directions: The analyses in the present article
are cross-sectional and generate important additional
questions. Longitudinal analysis of intracranial
arterial health parameters will be performed to
determine how these relate to the incidence and
speed of cognitive decline and the accumulation of
Alzheimer’s-related pathology.
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